4ufw: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Plasmodium vivax N-myristoyltransferase in complex with a pyridyl inhibitor (compound 22)== | ==Plasmodium vivax N-myristoyltransferase in complex with a pyridyl inhibitor (compound 22)== | ||
<StructureSection load='4ufw' size='340' side='right' caption='[[4ufw]], [[Resolution|resolution]] 1.50Å' scene=''> | <StructureSection load='4ufw' size='340' side='right'caption='[[4ufw]], [[Resolution|resolution]] 1.50Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4ufw]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Plavi Plavi]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UFW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UFW FirstGlance]. <br> | <table><tr><td colspan='2'>[[4ufw]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Plavi Plavi]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UFW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UFW FirstGlance]. <br> | ||
| Line 25: | Line 25: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Glycylpeptide N-tetradecanoyltransferase]] | [[Category: Glycylpeptide N-tetradecanoyltransferase]] | ||
[[Category: Large Structures]] | |||
[[Category: Plavi]] | [[Category: Plavi]] | ||
[[Category: Brannigan, J A]] | [[Category: Brannigan, J A]] | ||
Revision as of 13:45, 26 February 2020
Plasmodium vivax N-myristoyltransferase in complex with a pyridyl inhibitor (compound 22)Plasmodium vivax N-myristoyltransferase in complex with a pyridyl inhibitor (compound 22)
Structural highlights
Function[A5K1A2_PLAVS] Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins (By similarity).[RuleBase:RU000586] Publication Abstract from PubMedN-Myristoyltransferase (NMT) represents an attractive drug target in parasitic infections such as malaria due to its genetic essentiality and amenability to inhibition by drug-like small molecules. Scaffold simplification from previously reported inhibitors containing bicyclic cores identified phenyl derivative 3, providing a versatile platform to study the effects of substitution on the scaffold, which yielded pyridyl 19. This molecule exhibited improved enzyme and cellular potency, and reduced lipophilicity compared to inhibitor 3. Further structure-based inhibitor design led to the discovery of 30, the most potent inhibitor in this series, which showed single-digit nM enzyme affinity and sub-muM anti-plasmodial activity. Discovery of pyridyl-based inhibitors of -myristoyltransferase.,Yu Z, Brannigan JA, Rangachari K, Heal WP, Wilkinson AJ, Holder AA, Leatherbarrow RJ, Tate EW Medchemcomm. 2015 Oct 8;6(10):1767-1772. Epub 2015 Aug 19. PMID:26962430[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||||